WASHINGTON – The Office of the United States Trade Representative today announced the further extension of the COVID-related product exclusions in the China Section 301 Investigation. The exclusions were previously scheduled to expire on November 30, 2022. In light of the continuing efforts to combat COVID, the exclusions have been extended for an additional 90 days, through February 28, 2023.
The exclusions cover 81 medical-care products and were initially granted on December 29, 2020. Additional information is set out in the Federal Register notice, which can be viewed here.